Literature DB >> 22406596

BRCA and pancreatic cancer: selection of chemotherapy.

Richard Kim1, Jenifer Byer, Muhammad Wasif Saif.   

Abstract

Germline mutations in BRCA genes are associated with increased risk of pancreatic cancer. There are pre clinical data which suggests that DNA cross linking agents should be used in pancreatic cancer patients with BRCA mutations. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of pancreatic cancer with BRCA mutation. Only one study (Abstracts #217) was presented and it is described here.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22406596

Source DB:  PubMed          Journal:  JOP        ISSN： 1590-8577


  5 in total

1.  Ampulla of vater adenocarcinoma in a BRCA2 germline mutation carrier.

Authors:  Nana Aburjania; Alexander M Truskinovsky; Michael J Overman; Emil Lou
Journal:  J Gastrointest Cancer       Date:  2014-03

2.  Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts.

Authors:  Wei Zhan; Celeste A Shelton; Phil J Greer; Randall E Brand; David C Whitcomb
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

Review 3.  Germline mutations in pancreatic cancer and potential new therapeutic options.

Authors:  Rille Pihlak; Juan W Valle; Mairéad G McNamara
Journal:  Oncotarget       Date:  2017-04-20

Review 4.  The complexities of epidemiology and prevention of gastrointestinal cancers.

Authors:  Saba Haq; Shadan Ali; Ramzi Mohammad; Fazlul H Sarkar
Journal:  Int J Mol Sci       Date:  2012-10-01       Impact factor: 5.923

5.  Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment.

Authors:  Shibani Mukherjee; Aroumougame Asaithamby
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.